Antibody Blockade of the PSGL-1 Immune Checkpoint Enhances T Cell Responses to B Cell Lymphoma

Researchers investigated the potential of P-selectin glycoprotein ligand-1 (PSGL-1) antibody targeting in B cell lymphoma. Using allogeneic co-culture systems, they demonstrated that targeted antibody interventions against human PSGL-1 enhanced T cell activation and effector cytokine production in response to lymphoma cells.